Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ABCL AbCellera Biologics Inc
- Stocks
- Healthcare
- NASDAQ: ABCL
Price (delayed)
$2.1
Market cap
$626.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.56
Enterprise value
$505.76M
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners
Highlights
The company's quick ratio rose by 23% YoY
AbCellera Biologics's debt has decreased by 7% YoY but it has increased by 4.1% from the previous quarter
The company's revenue fell by 35% YoY and by 20% QoQ
The gross profit has contracted by 35% YoY and by 20% from the previous quarter
Key stats
What are the main financial stats of ABCL
Market
Valuations
Earnings
Shares outstanding
298.48M
Market cap
$626.82M
Enterprise value
$505.76M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.61
Price to sales (P/S)
27.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.88
Revenue
$23.12M
Gross profit
$23.12M
Operating income
-$322.53M
Net income
-$167.87M
EBIT
-$210.63M
EBITDA
-$113.8M
Free cash flow
-$143.29M
Per share
Balance sheet
Liquidity
EPS
-$0.56
EPS diluted
-$0.56
Free cash flow per share
-$0.48
Book value per share
$3.43
Revenue per share
$0.08
TBVPS
$4.22
Total assets
$1.34B
Total liabilities
$321.23M
Debt
$63.21M
Equity
$1.02B
Working capital
$689.58M
Debt to equity
0.06
Current ratio
10.15
Quick ratio
8.89
Net debt/EBITDA
1.06
Margins
Efficiency
Dividend
EBITDA margin
-492.3%
Gross margin
100%
Net margin
-726.2%
Operating margin
-1,395.3%
Return on assets
-12.2%
Return on equity
-15.7%
Return on invested capital
-19.3%
Return on capital employed
-16.6%
Return on sales
-911.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ABCL stock price
How has the AbCellera Biologics stock price performed over time
Intraday
1.94%
1 week
3.45%
1 month
-12.5%
1 year
-45.45%
YTD
-28.33%
QTD
-5.83%
Financial performance
How have AbCellera Biologics's revenue and profit performed over time
Revenue
$23.12M
Gross profit
$23.12M
Operating income
-$322.53M
Net income
-$167.87M
Gross margin
100%
Net margin
-726.2%
AbCellera Biologics's operating margin has shrunk by 120% YoY and by 28% QoQ
AbCellera Biologics's net margin has plunged by 77% YoY and by 29% from the previous quarter
ABCL's operating income is down by 42% year-on-year and by 2.5% since the previous quarter
The company's revenue fell by 35% YoY and by 20% QoQ
Price vs fundamentals
How does ABCL's price correlate with its fundamentals
Growth
What is AbCellera Biologics's growth rate over time
Valuation
What is AbCellera Biologics stock price valuation
P/E
N/A
P/B
0.61
P/S
27.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.88
ABCL's EPS is down by 8% YoY
ABCL's P/B is 81% below its 5-year quarterly average of 3.2 and 14% below its last 4 quarters average of 0.7
The equity has declined by 9% year-on-year and by 3.1% since the previous quarter
The P/S is 37% more than the 5-year quarterly average of 19.3 but 2.1% less than the last 4 quarters average of 27.1
The company's revenue fell by 35% YoY and by 20% QoQ
Efficiency
How efficient is AbCellera Biologics business performance
ABCL's ROS has plunged by 93% YoY and by 31% from the previous quarter
The company's return on invested capital fell by 27% YoY and by 6% QoQ
AbCellera Biologics's ROE has decreased by 25% YoY and by 5% from the previous quarter
The ROA has contracted by 24% YoY and by 5% from the previous quarter
Dividends
What is ABCL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ABCL.
Financial health
How did AbCellera Biologics financials performed over time
ABCL's current ratio is up by 31% YoY and by 3.5% QoQ
The company's quick ratio rose by 23% YoY
AbCellera Biologics's debt is 94% less than its equity
The equity has declined by 9% year-on-year and by 3.1% since the previous quarter
AbCellera Biologics's debt has decreased by 7% YoY but it has increased by 4.1% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.